MX2009012506A - Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. - Google Patents

Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.

Info

Publication number
MX2009012506A
MX2009012506A MX2009012506A MX2009012506A MX2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A MX 2009012506 A MX2009012506 A MX 2009012506A
Authority
MX
Mexico
Prior art keywords
synthesis
compositions
methods
atypical antipsychotic
antipsychotic agents
Prior art date
Application number
MX2009012506A
Other languages
English (en)
Inventor
Laxminarayan Bhat
Prabhu P Mohapatra
Seema Rani Bhat
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of MX2009012506A publication Critical patent/MX2009012506A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente invención proporciona derivados novedosos de quinolinona que pueden utilizarse ventajosamente para tratar la esquizofrenia y psicosis relacionadas tales como desorden bipolar maniaco agudo, desorden autista, y depresión.
MX2009012506A 2007-05-21 2008-05-21 Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona. MX2009012506A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93926207P 2007-05-21 2007-05-21
PCT/US2008/064433 WO2008144764A1 (en) 2007-05-21 2008-05-21 Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents

Publications (1)

Publication Number Publication Date
MX2009012506A true MX2009012506A (es) 2009-12-09

Family

ID=40072982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012506A MX2009012506A (es) 2007-05-21 2008-05-21 Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.

Country Status (13)

Country Link
US (1) US8247420B2 (es)
EP (1) EP2162135A4 (es)
JP (1) JP5466147B2 (es)
CN (1) CN101754761B (es)
AU (1) AU2008254585B2 (es)
BR (1) BRPI0811844A2 (es)
CA (1) CA2688784A1 (es)
IL (1) IL202003A (es)
MX (1) MX2009012506A (es)
NZ (1) NZ582124A (es)
RU (1) RU2497819C2 (es)
WO (1) WO2008144764A1 (es)
ZA (1) ZA200908753B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010217772B2 (en) * 2009-02-26 2014-10-23 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
EP3309151A1 (en) 2009-06-25 2018-04-18 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
PL395469A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
JP6787926B2 (ja) 2015-01-12 2020-11-18 レビバ ファーマシューティカルズ，インコーポレイティド 肺高血圧症の治療方法
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
RU2667954C2 (ru) * 2016-03-04 2018-09-25 Общество С Ограниченной Ответственностью "Валентек" Фармацевтическая композиция для лечения функциональных психических расстройств
KR102444803B1 (ko) * 2017-05-04 2022-09-19 익스시바 게엠베하 신규 조성물, 조합 및 그의 방법을 갖는 표적 약물 구제
WO2018234805A1 (en) * 2017-06-22 2018-12-27 Curadev Pharma Limited SMALL MOLECULAR MODULATORS OF HUMAN STING
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN115784983A (zh) * 2022-12-05 2023-03-14 井冈山大学 6-胺烷氧基-3,4-二氢喹啉酮衍生物及制备方法和应用
CN116496234A (zh) * 2023-02-09 2023-07-28 江苏润安制药有限公司 一种盐酸乌拉地尔关键中间体的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649364A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5649361A (en) * 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
US6174882B1 (en) * 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
SE0200301D0 (sv) 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
PL218788B1 (pl) * 2002-03-29 2015-01-30 Janssen Pharmaceutica Nv Znakowane radioaktywnie pochodne chinoliny i jej zastosowanie
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
BR0314393A (pt) * 2002-09-17 2005-07-19 Warner Lambert Co Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
EP1480953B2 (en) 2003-01-09 2010-08-18 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
PL1626721T3 (pl) * 2003-05-23 2017-05-31 Otsuka Pharmaceutical Co., Ltd. Pochodne karbostyrylu i stabilizatory nastroju do leczenia zaburzeń nastroju
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1797039A1 (en) 2004-09-13 2007-06-20 Matrix Laboratories Ltd Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
US7872132B2 (en) 2004-10-08 2011-01-18 Suven Life Sciences Limited Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole

Also Published As

Publication number Publication date
NZ582124A (en) 2012-07-27
JP2010528042A (ja) 2010-08-19
EP2162135A1 (en) 2010-03-17
BRPI0811844A2 (pt) 2014-11-18
RU2009147268A (ru) 2011-06-27
RU2497819C2 (ru) 2013-11-10
ZA200908753B (en) 2010-07-28
US8247420B2 (en) 2012-08-21
CN101754761B (zh) 2014-06-18
CA2688784A1 (en) 2008-11-27
EP2162135A4 (en) 2012-02-22
US20080293736A1 (en) 2008-11-27
AU2008254585A1 (en) 2008-11-27
CN101754761A (zh) 2010-06-23
AU2008254585B2 (en) 2013-09-26
IL202003A0 (en) 2010-06-16
WO2008144764A1 (en) 2008-11-27
IL202003A (en) 2013-11-28
JP5466147B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
MX2009012506A (es) Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.
MY161473A (en) Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX2011009568A (es) Inhibidores de la rho cinasa.
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MY153915A (en) Organic compounds
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
MX2011001679A (es) Derivados de flavina.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MY152749A (en) Pyrazole and fused pyrazole glucokinase activators
GEP20125652B (en) cMET INHIBITORS
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
TW201713640A (en) Bruton's tyrosine kinase inhibitors
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration